NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

OS confoundment unlikely, because, in a prior trial, DCVax-L only demonstrated systemic immune response activity (matching antigens between t-cells and tumor after injection) in patients that were not progressing at time of initial injections and/or had complete original resection. Thus, upon recurrence, we know from the Journal only three recurrent surgery patients followed that with DCVax-L. Those three + a few(?) misdiagnosed psPD crossovers from placebo are really the only ones that might cause some confoundment. Really, I think perhaps two of the second surgery patients that went on dcvax-l were in the treatment arm -- recalling Sunday and somebody else. I think the patients that might potentially cause crossover confoundment make up less than a handful out of the 99 control patients (unless the therapy became more potent along the way). Not very many.